Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2017

March 24, 2017 Corporate

Nippon Shinyaku enters into a license agreement with Delta-Fly Pharma on DFP-10917, a therapeutic agent for relapsed/refractory acute myeloid leukemia

Nippon Shinyaku Co., Ltd. (HQ: Kyoto, President: Shigenobu Maekawa) and Delta-Fly Pharma, Inc. (HQ: Tokushima, Japan, President: Kiyoshi Eshima) announced that the two companies have signed a license agreement on DFP-10917 for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). This agreement enables Nippon Shinyaku to exclusively develop and commercialize DFP-10917 in Japan.


DFP-10917 is a novel deoxycytidine analog that induces DNA damage by the different mechanism of action from other nucleoside analogs. Delta-Fly Pharma, Inc. has completed a phase 1/2 clinical study of DFP-10917 for r/r AML initiated at The University of Texas MD Anderson Cancer Center in the US.


In the study, DFP-10917 demonstrated a significant anti-leukemic activity with tolerable safety profile in r/r AML by low dose continuous infusion. On the basis of the result, a global phase 3 clinical study is planned in 2017.


DFP-10917 is expected to fulfill an unmet medical need in the treatment of r/r AML. Nippon Shinyaku aims to contribute to improving treatment for elderly patients with r/r AML by launching DFP-10917 in Japan as soon as possible.




Delta-Fry Pharma, Inc. is a privately held bio-pharmaceutical company established in 2010 with headquarters in Tokushima, Japan. The company is engaged in the research and development of drugs for the treatment of cancer.